カテゴリ： Allied Market Research, 世界, 医療/バイオ

骨系統疾患のグローバル市場（2021～2031）：モルキオ症候群A型、X連鎖性低リン血症、低ホスファターゼ症、その他

■ 英語タイトル：Skeletal Dysplasia Market By Type (Morquio A syndrome, X-linked hypophosphatemia, Hypophosphatasia, Others), By Treatment (Enzyme replacement therapy, Human monoclonal antibody, Others), By Distribution Channel (Hospital pharmacies, Drug store and specialty pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC095）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC095
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：355
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[骨系統疾患のグローバル市場（2021～2031）：モルキオ症候群A型、X連鎖性低リン血症、低ホスファターゼ症、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には1,638.10百万ドルであった世界の骨系統疾患市場規模が2031年には2,360.51百万ドルへ及び、2022年から2031年の間にCAGR 3.7％増加すると推測されています。本調査資料では、骨系統疾患の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、種類別（モルキオ症候群A型、X連鎖性低リン血症、低ホスファターゼ症、その他）分析、治療法別（酵素補充療法、ヒトモノクローナル抗体、その他）分析、流通チャネル別（病院内薬局、ドラッグストア・専門薬局、オンラインプロバイダー）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、Amgen Inc.、AstraZeneca plc、Cipla Ltd、Merck KGaA、Ascendis pharma a/s、F. Hoffmann-La Roche AG、Eli Lilly and Company、Teva Pharmaceutical Industries Ltd.、Pfizer, Inc.、Biomarin Pharmaceuticals Inc.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の骨系統疾患市場規模：種類別
- モルキオ症候群A型
- X連鎖性低リン血症
- 低ホスファターゼ症
- その他骨系統疾患の市場規模
・世界の骨系統疾患市場規模：治療法別
- 酵素補充療法における市場規模
- ヒトモノクローナル抗体における市場規模
- その他治療法における市場規模
・世界の骨系統疾患市場規模：流通チャネル別
- 病院内薬局チャネルの市場規模
- ドラッグストア・専門薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
・世界の骨系統疾患市場規模：地域別
- 北米の骨系統疾患市場規模
- ヨーロッパの骨系統疾患市場規模
- アジア太平洋の骨系統疾患市場規模
- 中南米/中東・アフリカの骨系統疾患市場規模
・競争状況
・企業情報

骨系統疾患の世界市場規模は2021年に16億3,810万ドル、2031年には23億6,051万ドルに達すると予測され、2022年から2031年までの年平均成長率は3.7%となる見込みです。

骨系統疾患は450種類以上ある希少疾患です。軟骨と骨の成長と発育がこの病気の影響を受けます。この疾患の重症度は、中立的な致死性から成人期の成長障害まで様々です。骨系統疾患はまれな疾患であるため、診断が複雑です。主な症状としては、大頭の変形、成長の遅れ、湾曲した骨、短い上腕と大腿、関節痛や関節炎などがあります。

この疾患は小児に多く、早期治療が啓発に役立ちます。この疾患は、胎児の発育中に突然変異を起こすか、両親から受け継いだ欠陥遺伝子の結果です。防御遺伝子の特定は最も複雑です。そのため、企業はこの稀な疾患の治療法を見つけるための研究開発に多額の投資を行っています。骨系統疾患市場は、骨疾患を患う小児人口の増加、革新的技術の発売、医療費の増加、政府支援の強化などにより、予測期間中に大きな市場成長が見込まれると推定されます。また、研究開発への投資増加、パイプライン候補の充実、医療インフラ整備への支出増加も市場の成長を促進します。しかし、治療費の高騰は市場成長の妨げになると予想されます。これとは対照的に、公共部門および民間部門における医療投資の急増は、骨系統疾患市場に大きな成長機会をもたらすと予想されます。

骨系統疾患市場は、種類、治療法、流通チャネル、地域によって区分されます。
種類別では、市場はモルキオA症候群、X連鎖性低リン血症、低リン血症、その他に二分されます。
治療法別では、市場は酵素補充療法、ヒトモノクローナル抗体、その他に分類されます。
販売チャネル別では、病院薬局、ドラッグストア、専門薬局、オンラインプロバイダーに分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

本レポートは、世界の骨系統疾患市場で事業を展開する主要企業の包括的な分析を提供します。本レポートに掲載されている主要企業には、Amgen Inc.、Ascendis Pharma a/s、AstraZeneca plc.、Biomarin Pharmaceuticals Inc.、Cipla Ltd.、Eli Lilly and Company、F. Hoffmann-La Roche AG、Merck KGaA、Pfizer, Inc.、Teva Pharmaceutical Industries Ltd.などがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの骨系統疾患市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、優勢な骨系統疾患市場の機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益志向のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・骨系統疾患市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・骨系統疾患の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
モルキオA症候群
X連鎖性低リン血症
低リン血症
その他

治療法別
酵素補充療法
ヒトモノクローナル抗体
その他

販売チャネル別
病院薬局
ドラッグストア・専門薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
その他のアジア太平洋地域
・LAMEA
ラテンアメリカ
中東・アフリカ

〈主要市場プレイヤー〉
Amgen Inc.
AstraZeneca plc
Cipla Ltd
Merck KGaA
Ascendis pharma a/s
F. Hoffmann-La Roche AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Biomarin Pharmaceuticals Inc.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of skeletal dysplasia
3.4.1.2. Commercialization of novel drugs and presence of pipeline products
3.4.1.3. Increase in government expenditure on healthcare
3.4.1.4. Increase in the number of clinical trials and collaborative research for skeletal dysplasia treatment

3.4.2. Restraints
3.4.2.1. Strict regulatory rules and high cost

3.4.3. Opportunities
3.4.3.1. Growth opportunities in the emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SKELETAL DYSPLASIA MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Morquio A syndrome
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. X-linked hypophosphatemia
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Hypophosphatasia
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: SKELETAL DYSPLASIA MARKET, BY TREATMENT
5.1. Overview
5.1.1. Market size and forecast
5.2. Enzyme replacement therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Human monoclonal antibody
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug store and specialty pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: SKELETAL DYSPLASIA MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Treatment
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Treatment
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Treatment
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Treatment
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Treatment
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Treatment
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Treatment
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Treatment
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Treatment
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Treatment
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Treatment
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Treatment
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Treatment
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Treatment
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Treatment
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Rest of Asia-Pacific
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Treatment
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Treatment
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Treatment
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Treatment
7.5.5.2.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Amgen Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. AstraZeneca plc
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Eli Lilly and Company
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Cipla Ltd
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Biomarin Pharmaceuticals Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Teva Pharmaceutical Industries Ltd.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Merck KGaA
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Ascendis pharma a/s
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Pfizer, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. F. Hoffmann-La Roche AG
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. SKELETAL DYSPLASIA MARKET FOR MORQUIO A SYNDROME, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. SKELETAL DYSPLASIA MARKET FOR X-LINKED HYPOPHOSPHATEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. SKELETAL DYSPLASIA MARKET FOR HYPOPHOSPHATASIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. SKELETAL DYSPLASIA MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. GLOBAL SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 07. SKELETAL DYSPLASIA MARKET FOR ENZYME REPLACEMENT THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. SKELETAL DYSPLASIA MARKET FOR HUMAN MONOCLONAL ANTIBODY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. SKELETAL DYSPLASIA MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 11. SKELETAL DYSPLASIA MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. SKELETAL DYSPLASIA MARKET FOR DRUG STORE AND SPECIALTY PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. SKELETAL DYSPLASIA MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. SKELETAL DYSPLASIA MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 21. U.S. SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 24. CANADA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 26. MEXICO SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 27. MEXICO SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 30. EUROPE SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. EUROPE SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GERMANY SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 34. GERMANY SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. FRANCE SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. FRANCE SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 37. FRANCE SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. UK SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. UK SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 40. UK SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ITALY SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. ITALY SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 43. ITALY SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. SPAIN SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. SPAIN SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 46. SPAIN SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. REST OF EUROPE SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 49. REST OF EUROPE SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 53. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 54. JAPAN SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. JAPAN SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 56. JAPAN SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. CHINA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. CHINA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 59. CHINA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 62. INDIA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 65. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 66. LAMEA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 67. LAMEA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 68. LAMEA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 69. LAMEA SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 70. LATIN AMERICA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LATIN AMERICA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LATIN AMERICA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 75. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. AMGEN INC.: KEY EXECUTIVES
TABLE 77. AMGEN INC.: COMPANY SNAPSHOT
TABLE 78. AMGEN INC.: PRODUCT SEGMENTS
TABLE 79. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 80. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 81. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 82. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 83. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 84. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 85. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 86. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 87. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 88. CIPLA LTD: KEY EXECUTIVES
TABLE 89. CIPLA LTD: COMPANY SNAPSHOT
TABLE 90. CIPLA LTD: PRODUCT SEGMENTS
TABLE 91. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 92. BIOMARIN PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 93. BIOMARIN PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 94. BIOMARIN PHARMACEUTICALS INC.: PRODUCT SEGMENTS
TABLE 95. BIOMARIN PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 96. BIOMARIN PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 101. MERCK KGAA: KEY EXECUTIVES
TABLE 102. MERCK KGAA: COMPANY SNAPSHOT
TABLE 103. MERCK KGAA: PRODUCT SEGMENTS
TABLE 104. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 105. ASCENDIS PHARMA A/S: KEY EXECUTIVES
TABLE 106. ASCENDIS PHARMA A/S: COMPANY SNAPSHOT
TABLE 107. ASCENDIS PHARMA A/S: PRODUCT SEGMENTS
TABLE 108. ASCENDIS PHARMA A/S: PRODUCT PORTFOLIO
TABLE 109. ASCENDIS PHARMA A/S: KEY STRATERGIES
TABLE 110. PFIZER, INC.: KEY EXECUTIVES
TABLE 111. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 112. PFIZER, INC.: PRODUCT SEGMENTS
TABLE 113. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 114. PFIZER, INC.: KEY STRATERGIES
TABLE 115. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 116. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 117. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
TABLE 118. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 骨異形成症のグローバル市場（2022年-2029年）：X連鎖性低リン血症、低リン血症、軟骨形成不全、進行性骨異形成症、多発性骨軟骨腫、その他
  • 世界のHPP（低ホスファターゼ症）市場：市場規模・動向・予測（2022～2030）
  • 色素異常症治療のグローバル市場（2021〜2031）：白斑、肝斑、その他
  • コンパニオンアニマル関節炎のグローバル市場（2021～2031）：犬、猫、馬
  • クリ・デュ・チャット症候群治療のグローバル市場（2021〜2031）：理学療法、言語療法、作業療法
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC095 )"骨系統疾患のグローバル市場（2021～2031）：モルキオ症候群A型、X連鎖性低リン血症、低ホスファターゼ症、その他" (英文：Skeletal Dysplasia Market By Type (Morquio A syndrome, X-linked hypophosphatemia, Hypophosphatasia, Others), By Treatment (Enzyme replacement therapy, Human monoclonal antibody, Others), By Distribution Channel (Hospital pharmacies, Drug store and specialty pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。